This issue, welcomes original research articles, systematic reviews, and meta-analyses that examine the therapeutic benefits, adverse event profiles, and real-world effectiveness of hypoglycemic agents. Of particular interest are studies that bridge the gap between controlled clinical trial data and actual clinical practice, including observational studies and pharmacovigilance reports.
Key topics of interest include:
- Comparative effectiveness and safety of novel and established hypoglycemic drugs
- Long-term outcomes and cardiovascular safety profiles
- Real-world treatment patterns and adherence
- Pharmacovigilance and post-marketing surveillance of hypoglycemic drugs, including signal detection, risk assessment, and management of adverse drug reactions
- Special populations including elderly patients, those with renal or hepatic impairment, and pregnant women
- Pharmacoeconomic evaluations and health outcomes research
- Emerging therapies and combination treatment strategies
